1.The Factors for the Aggression in Patients with On-Line Game Addiction : Behavioral Inhibition/Activation System and Comorbid Disease.
Jeongha PARK ; Young Sik LEE ; Bung Nyun KIM ; Jae Hoon CHEONG ; Doug Hyun HAN
Journal of Korean Neuropsychiatric Association 2013;52(2):84-90
OBJECTIVES: Based on the debate between on-line game addiction and aggressive behaviors view, the aim of this study was to investigate the factors for aggression in patients with on-line game addiction. METHODS: A total of 107 adolescent patients with on-line game addiction were enrolled in an online game clinic and research center, OO hospital. In order to rule out psychiatric Axis I comorbidity, all participants were interviewed by a psychiatrist. In addition, their symptoms were assessed using the Young Internet Assessment Scale-Korean (YIAS-K), Korean Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale, Child depression index, Aggression scale extracted from Korean child behavior checklist, and Behavioral inhibition system (BIS)/Behavioral activation system (BAS). The participants were classified according to three groups; pure on-line game addiction group (pure-Game), on-line game addiction with attention-deficit hyperactivity syndrome (ADHD-Game) group, and on-line game addiction with depression group (Dep-Game). RESULTS: Thirty seven subjects in the pure-Game group, 53 subjects in the ADHD-Game group, and 39 subjects in the Dep-Game group showed significant differences in severity of on-line game addiction and aggression. Both the ADHD-Game and Dep-Game groups showed higher YIAS-K and aggression scale scores, compared to the pure on-line game addiction group. Aggression scale showed positive correlation with BAS-drive in the ADHD-Game group. Aggression also showed positive correlation with BIS in the Dep-Game group. CONCLUSION: The current results suggested that the comorbidity of online game addiction would be a critical factor in aggression and impulsivity in patients with on-line game addiction.
Adolescent
;
Aggression
;
Axis, Cervical Vertebra
;
Checklist
;
Child
;
Child Behavior
;
Comorbidity
;
Depression
;
Humans
;
Internet
;
Psychiatry
2.Clinical efficacy of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in patients with multidrug-resistant bacteremia: a single-center study in Korea
Jeongha MOK ; Eun Jung JO ; Jung Seop EOM ; Mi Hyun KIM ; Ki Uk KIM ; Hye Kyung PARK ; Min Ki LEE ; Kwangha LEE
The Korean Journal of Internal Medicine 2019;34(5):1058-1067
BACKGROUND/AIMS:
Matrix-assisted laser desorption/ionization time-of-f light mass spectrometry (MALDI-TOF MS) is a new diagnostic tool for microorganism identification. The clinical usefulness of this approach has not been widely examined in Korea. This retrospective pre–post-intervention quasi-experimental study examined the effect of MALDI-TOF MS on patients with multidrug-resistant (MDR) bacteremia in the intensive care unit (ICU).
METHODS:
All consecutive patients with MDR bacteremia in the ICU of a tertiary care hospital between March 2011 and February 2013 and between March 2014 and February 2016 were enrolled. MALDI-TOF MS was introduced between these periods. In the pre-intervention and intervention groups, microorganisms were identified by conventional means and by MALDI-TOF MS, respectively. The groups were compared in terms of time from venipuncture to microorganism identification and antimicrobial susceptibility test results.
RESULTS:
In total, 187 patients (mean age, 61.0 years; 56.7% male) were enrolled. Of these, 97 and 90 were in the pre-intervention and intervention groups, respectively. The intervention group had a significantly shorter time from venipuncture to microorganism identification and antimicrobial susceptibility test results (82.5 ± 21.6 hours vs. 92.3 ± 40.4 hours, p = 0.038). The antibiotics were adjusted in 52 patients (26 each in the pre-intervention and intervention groups) based on these results. These groups did not differ in terms of time from venipuncture to antibiotic adjustment, and multivariate regression analysis showed that MALDI-TOF MS–based microorganism identification was not associated with 28-day mortality.
CONCLUSIONS
Our study showed that MALDI-TOF MS accelerated microorganism identification in patients with MDR bacteremia, but did not inf luence 28-day mortality.
3.Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Comparison of Pre- and Post-Public–Private Mix Periods
Yewon KANG ; Eun-Jung JO ; Jung Seop EOM ; Mi-Hyun KIM ; Kwangha LEE ; Ki Uk KIM ; Hye-Kyung PARK ; Min Ki LEE ; Jeongha MOK
Tuberculosis and Respiratory Diseases 2021;84(1):74-83
Background:
This study compared the treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) before and after the implementation of public–private mix (PPM). Factors affecting treatment success were also investigated.
Methods:
Data from culture-confirmed pulmonary MDR-TB patients who commenced MDR-TB treatment at Pusan National University Hospital between January 2003 and December 2017 were retrospectively reviewed. Patients were divided into two groups in terms of PPM status: pre-PPM period, patients who commenced MDR-TB treatment between 2003 and 2010; and post-PPM period, patients treated between 2011 and 2017.
Results:
A total of 176 patients were included (64 and 112 in the pre- and post-PPM periods, respectively). 36.9% of the patients were resistant to a fluoroquinolone or a second-line injectable drug, or both. The overall treatment success rate was 72.7%. The success rate of post-PPM patients was higher than that of pre-PPM patients (79.5% vs. 60.9%, p=0.008). Also, loss to follow-up was lower in the post-PPM period (5.4% vs. 15.6%, p=0.023). In multivariate regression analysis, age ≥65 years, body mass index ≤18.5 kg/m2, previous TB treatment, bilateral lung involvement, and extensively drug-resistant (XDR)- or pre-XDR-TB were associated with poorer treatment outcomes. However, the use of bedaquiline or delamanid for ≥1 month increased the treatment success.
Conclusion
The treatment success rate in MDR-TB patients was higher in the post-PPM period than in the pre-PPM period, particularly because of the low rate of loss to follow-up. To ensure comprehensive patient-centered PPM in South Korea, investment and other support must be adequate.
4.The Additive Impact of Transbronchial Cryobiopsy Using a 1.1-mm Diameter Cryoprobe on Conventional Biopsy for Peripheral Lung Nodules
Soo Han KIM ; Jeongha MOK ; Eun-Jung JO ; Mi-Hyun KIM ; Kwangha LEE ; Ki Uk KIM ; Hye-Kyung PARK ; Min Ki LEE ; Jung Seop EOM
Cancer Research and Treatment 2023;55(2):506-512
Purpose:
The diagnostic yield of transbronchial biopsy (TBB) using radial probe endobronchial ultrasound (RP-EBUS) is 71%, which is lower than that of transthoracic needle biopsy. We investigated the performance and safety of sequential transbronchial cryobiopsy (TBC) using a novel 1.1-mm diameter cryoprobe, after conventional TBB using RP-EBUS for the diagnosis of peripheral lung lesions (PLLs).
Materials and Methods:
From April 2021 to November 2021, 110 patients who underwent bronchoscopy using RP-EBUS for the diagnosis of PLL ≤ 30 mm were retrospectively included in our study. All records were followed until June 2022.
Results:
The overall diagnostic yield of combined TBB and TBC was 79.1%, which was higher than 60.9% of TBB alone (p=0.005). The diagnostic yield of sequential TBC was 65.5%, which increased the overall diagnostic yield by 18.2%. The surface area of tissues by TBC (mean area, 18.5 mm2) was significantly larger than those of TBB by 1.5-mm forceps (3.4 mm2, p < 0.001) and 1.9-mm forceps (3.7 mm2, p=0.011). In the multivariate analysis, PLLs with the longest diameter of ≤ 22 mm were found to be related to additional diagnostic benefits from sequential TBC (odds ratio, 3.51; 95% confidence interval, 1.043 to 11.775; p=0.042). Complications were found in 10.5% of the patients: pneumothorax (1.0%), infection (1.0%), and significant bleeding (8.6%). None of the patients developed any life-threatening complications.
Conclusion
Sequential TBC with a 1.1-mm cryoprobe improved the performance of conventional TBB using RP-EBUS without serious complications.
5.Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
Soo Han KIM ; Eun Jung JO ; Jeongha MOK ; Kwangha LEE ; Ki Uk KIM ; Hye-Kyung PARK ; Min Ki LEE ; Jung Seop EOM ; Mi-Hyun KIM
The Korean Journal of Internal Medicine 2023;38(2):218-225
Background/Aims:
Despite the obvious benefits of adding immune checkpoint inhibitors to platinum-etoposide chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC), real-world data remain scarce.
Methods:
This retrospective study included 89 patients with ES-SCLC treated with platinum-etoposide chemotherapy alone (chemo-only group; n = 48) or in combination with atezolizumab (atezolizumab group; n = 41) and compared the survival outcomes between these two groups.
Results:
Overall survival (OS) was significantly longer in the atezolizumab group than in the chemo-only group (15.2 months vs. 8.5 months; p = 0.047), whereas the median progression-free survival was almost the same (5.1 months vs. 5.0 months) in both groups (p = 0.754). Subsequent multivariate analysis revealed that thoracic radiation (hazard ratio [HR], 0.223; 95% confidence interval [CI], 0.092–0.537; p = 0.001) and atezolizumab administration (HR, 0.350; 95% CI, 0.184–0.668; p = 0.001) were favorable prognostic factors for OS. In the thoracic radiation subgroup, patients who received atezolizumab demonstrated favorable survival outcomes and no grade 3–4 adverse events (AEs).
Conclusions
The addition of atezolizumab to platinum-etoposide resulted in favorable outcomes in this real-world study. Thoracic radiation was associated with improved OS and acceptable AE risk in combination with immunotherapy in patients with ES-SCLC.
6.Predicting Mortality in Patients with Tuberculous Destroyed Lung Receiving Mechanical Ventilation.
Won Young KIM ; Mi Hyun KIM ; Eun Jung JO ; Jung Seop EOM ; Jeongha MOK ; Ki Uk KIM ; Hye Kyung PARK ; Min Ki LEE ; Kwangha LEE
Tuberculosis and Respiratory Diseases 2018;81(3):247-255
BACKGROUND: Patients with acute respiratory failure secondary to tuberculous destroyed lung (TDL) have a poor prognosis. The aim of the present retrospective study was to develop a mortality prediction model for TDL patients who require mechanical ventilation. METHODS: Data from consecutive TDL patients who had received mechanical ventilation at a single university-affiliated tertiary care hospital in Korea were reviewed. Binary logistic regression was used to identify factors predicting intensive care unit (ICU) mortality. A TDL on mechanical Ventilation (TDL-Vent) score was calculated by assigning points to variables according to β coefficient values. RESULTS: Data from 125 patients were reviewed. A total of 36 patients (29%) died during ICU admission. On the basis of multivariate analysis, the following factors were included in the TDL-Vent score: age ≥65 years, vasopressor use, and arterial partial pressure of oxygen/fraction of inspired oxygen ratio <180. In a second regression model, a modified score was then calculated by adding brain natriuretic peptide. For TDL-Vent scores 0 to 3, the 60-day mortality rates were 11%, 27%, 30%, and 77%, respectively (p<0.001). For modified TDL-Vent scores 0 to ≥3, the 60-day mortality rates were 0%, 21%, 33%, and 57%, respectively (p=0.001). For both the TDL-Vent score and the modified TDL-Vent score, the areas under the receiver operating characteristic curve were larger than that of other illness severity scores. CONCLUSION: The TDL-Vent model identifies TDL patients on mechanical ventilation with a high risk of mortality. Prospective validation studies in larger cohorts are now warranted.
Cohort Studies
;
Humans
;
Intensive Care Units
;
Korea
;
Logistic Models
;
Lung*
;
Mortality*
;
Multivariate Analysis
;
Natriuretic Peptide, Brain
;
Oxygen
;
Partial Pressure
;
Prognosis
;
Prospective Studies
;
Respiration, Artificial*
;
Respiratory Insufficiency
;
Retrospective Studies
;
ROC Curve
;
Tertiary Healthcare
;
Tuberculosis